Connect & Inspire
Share Your Story
Explore & Discover
Treatment & Care
Press Room
Subscribe
LATEST POSTS
Facing a Life-Threatening Disease with Your Partner
When Oliver was diagnosed with osteosarcoma at age 20, Carys applied her nursing training to care for him throughout his treatment.
An International Dog Day Tribute to a Man’s Best Friend Lost to Osteosarcoma
“Chief Texan” and popular podcaster, Jay B Sauceda, recalls Carl, his beloved Corgi who suffered from osteosarcoma, the most common bone cancer in adolescents and canines.
Doctors diagnose advanced cancer—in a dinosaur
Author: Gretchen Vogel, Published in: Science magazine
Connect & Inspire
Stories of inspiration, community, and survival
Facing a Life-Threatening Disease with Your Partner
When Oliver was diagnosed with osteosarcoma at age 20, Carys applied her nursing training to care for him throughout his treatment.
An International Dog Day Tribute to a Man’s Best Friend Lost to Osteosarcoma
“Chief Texan” and popular podcaster, Jay B Sauceda, recalls Carl, his beloved Corgi who suffered from osteosarcoma, the most common bone cancer in adolescents and canines.
Turning a Cancer Diagnosis Into an Opportunity to Raise Awareness
After Oliver was diagnosed with osteosarcoma, he decided to celebrate his 21st birthday with a fund-raiser to help other young people suffering from the disease.
Share Your Story
Fill out the form below to tell us about yourself. Sharing stories of osteosarcoma families helps us raise awareness and funds for much-needed research.
Gavin, Osteosarcoma Patient
Explore & Discover
Stories of research, progress and exploration
The Osteosarcoma Institute to Announce New Grant Recipients
A record 26 submissions will result in grantees who are working to transform research and treatment for osteosarcoma, a rare form of bone cancer ...
A Brief History of Osteosarcoma Treatment
By Lee Helman, MD
There has been a lack of improvement in outcomes for osteosarcoma patients over the last 40 years. Osteosarcoma is a very ...
Treatment and Care
Coming Soon!
Press Room
OSI News & updates
A Phase II clinical trial funded by The Osteosarcoma Institute is now enrolling
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment
Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates
Novel approach paves the way for vast expansion in the number of drugs targeting osteosarcoma
The Osteosarcoma Institute to Fund Clinical Trial in Recurrent Osteosarcoma
The Osteosarcoma Institute (OSI) announced today that it has awarded a grant to Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for a Phase II single arm study of olaparib (an FDA-approved PARP inhibitor) and ceralacertib/AZD6738 (an investigational ATR kinase inhibitor) in ...